Background: Reliability parameters of clinical measures should be sufficient in order to adequately monitor disease course and evaluate treatment in patients with Multiple Sclerosis (MS). The aim of this study was to assess the reliability of the Timed 25-Foot-Walk (T25FW) in patients with MS.
Methods: MS patients performed the T25FW twice with approximately one year in between. After the second measurement, they answered an anchor question using a three-point Likert scale. Taking the non-normal distribution of the T25FW into account, intraclass correlation coefficient (ICC), standard error of the mean (SEM) and smallest detectable change (SDC) were computed.
Results: 118 MS patients (76.3 % females, mean age 48.2 years) were included. Of these patients, 73 reported no change on the anchor question. They completed the T25FW at baseline in 4.7s (IQR 4.3-5.4s, n = 72) and at follow-up in 4.9s (IQR 4.3-5.9s, n = 73). The ICC was 0.895, the SEM was 0.037. The SDC was higher for higher mean T25FW and can be computed for each mean T25FW by 0.23*mean T25FW.
Conclusion: Overall, in patients with MS, the T25FW has a sufficient reliability as measured with the ICC, however the SDC of the T25FW increased when patients perform worse on the T25FW (i.e. have a lower walking speed). Because this test is often used in MS patients with limited walking ability, these findings are important to keep in mind when interpreting the re-test scores of the T25FW.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2024.105731 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with multiple sclerosis.
Mult Scler Relat Disord
December 2024
Exercise Biology, Department of Public Health, Aarhus University, Denmark.
Unlabelled: This review investigated the psychometric properties of the most commonly used short-, long-, complex- and patient-reported walking outcome measures in multiple sclerosis(MS): the timed-25-foot walk test (T25FW), the six-minute walk test (6MWT), the six-spot step-test (SSST), and the 12-item MS walking scale (MSWS-12), along with reported reference data of these tests.
Methods: Based on PubMed and Embase searches, psychometric as well as descriptive data of T25FW, 6MWT, SSST, and MSWS-12 were extracted from studies evaluating persons with MS (pwMS). Descriptive data was also extracted from healthy controls (HC), if reported.
Effects of Transcranial and Trans-Spinal Direct Current Stimulation Combined with Robot-Assisted Gait Training on Gait and Fatigue in Patients with Multiple Sclerosis: A Double-Blind, Randomized, Sham-Controlled Study.
J Clin Med
December 2024
Toledo Physiotherapy Research Group (GIFTO), Faculty of Physiotherapy and Nursing of Toledo, Universidad de Castilla-La Mancha, 45004 Toledo, Spain.
Multiple Sclerosis (MS) is a chronic neurological condition that impairs motor and sensory functions, particularly gait. Non-invasive neuromodulation techniques aim to enhance functional recovery and motor-cognitive outcomes, though their effectiveness remains debated. This study compared the effects of transcranial direct current stimulation (tDCS) and trans-spinal direct current stimulation (tsDCS), combined with robotic-assisted gait training (RAGT), on motor function and fatigue in people with MS (pwMS).
View Article and Find Full Text PDFAssociation of disability, walking, manual dexterity, and quality of life with sexual dysfunction in multiple sclerosis patients.
Acta Neurol Belg
December 2024
Department of Biostatistic, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, MD, Turkey.
Background/objective: This study aims to examine the relationship between sexual dysfunction and walking ability, manual dexterity, disability, and quality of life in patients with multiple sclerosis.
Methods: 51 sexually active MS patients (28 females and 23 males) participated in the study. Demographic data were recorded for all patients.
Safety and efficacy of omaveloxolone v/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16 years: a systematic review.
Orphanet J Rare Dis
December 2024
Discovery Research Division, Indian Council of Medical Research (ICMR) Headquarters, V. Ramalingaswami Bhawan, Ansari Nagar, P.O. Box 4911, New Delhi, 110029, India.
Background: Friedreich's ataxia (FA) is a rare genetic disorder caused by silencing of the frataxin gene (FXN), which leads to multiorgan damage. Nrf2 is a regulator of FXN, which is a modulator of oxidative stress in animals and humans. Omaveloxolone (Omav) is an Nrf2 activator and has been reported to have antioxidative potential in various disease conditions.
View Article and Find Full Text PDFA Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project.
Cureus
November 2024
Neurology, Hospital Ramón y Cajal, Madrid, ESP.
Objective: The diagnosis of secondary progressive multiple sclerosis (SPMS) is often established retrospectively leading to a delay in detection. This work presents a clinical care algorithm that aims to facilitate the recognition of the secondary progressive phase of the disease, analyzing its usefulness and the feasibility of its implementation in routine clinical practice.
Methods: The algorithm was developed in four phases: 1) choice of validated diagnostic tools for the detection of progression; 2) assessment of these tools based on experience of use, applicability, time consumed, perceived usefulness and suitability for a profile of a patient in transition to SPMS; 3) framework and final sequence of application; 4) feasibility evaluation through application in clinical practice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!